为探究 G 蛋白偶联受体（GPCRs）药物研发趋势，研究发现众多成果，为后续研发提供参考。 G 蛋白偶联受体（G protein-coupled receptors，GPCRs）是最大的药物靶点家族之一，这体现出它们参与了众多病理生理过程。在这篇综述中，研究人员分析了 GPCR 超家族的药物研发 ...

The adrenaline receptor studied is a member of the G protein-coupled receptor (GPCR) family, and this family is the target of one-third of all Food and Drug Administration (FDA)-approved drugs.

未来工作需拓展至非GPCR靶点，并开发可解释的端到端架构。这项成果不仅为药物安全性评估提供了新工具，更为网络医学时代的靶点发现树立了新范式，其酵母平台与计算方法相结合的策略，为天然产物生物合成等生物技术领域开辟了新途径。

Researchers have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs. The discovery opens the ...

G protein-coupled receptors (GPCRs) are expressed on the surface of cells and regulate a range of important functions. Because they are involved in so many sensory and physiological processes, ...

Historically, GPCRs have been one of the most important targets for drug discovery. In fact, around 30 % of all currently marketed drugs target GPCRs. Despite this, a significant number of GPCRs ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus ...

GPCR drug discovery and development specialist Confo Therapeutics NV has closed a €60 million (US$65.2 million) series B round that will fund a significant expansion of the inhouse portfolio while it ...